Gender (%) |
Female |
5 (62.5) |
Age (yr, median [IQR]) |
|
48 [41–53] |
BMI (kg m−1, median [IQR]) |
|
29 [26–35] |
ASA physical status (%) |
1 |
0 (0.0) |
2 |
2 (25.0) |
3 |
5 (62.5) |
4 |
1 (12.5) |
Ischaemic heart disease (%) |
|
0 (0.0) |
Heart failure (%) |
|
0 (0.0) |
Cerebrovascular accident (%) |
Ischaemic |
8 (100.0) |
Haemorrhagic |
0 (0.0) |
Diabetes mellitus (%) |
No |
7 (87.5) |
Non-insulin dependent |
0 (0.0) |
Insulin dependent |
1 (12.5) |
Hypertension (%) |
|
4 (50.0) |
Vascular disease (%) |
No |
5 (62.5) |
Peripheral |
0 (0.0) |
Central |
3 (32.5) |
Elevated creatinine level (%) |
|
0 (0.0) |
Anticoagulants (%) |
|
8 (100.0) |
Beta blocking agents (%) |
|
1 (12.5) |
Renin–angiotensin–aldosterone system inhibitors (%) |
|
2 (25.0) |
Calcium antagonist (%) |
|
1 (12.5) |
Diuretics (%) |
|
0 (0.0) |
Statins (%) |
|
5 (62.5) |
Indication for cerebral bypass (%) |
Moyamoya disease |
5 (62.5) |
|
Carotid occlusion |
3 (37.5)
|
|
Intraoperative characteristics
|
|
Patients (N = 8)∗
|
Cases (N = 10) †
|
Duration of surgery (min, median [IQR]) |
|
299 [260–357] |
297 [260–342] |
pH before start of study (mm Hg, median [IQR]) |
|
7.39 [7.38–7.40] |
7.39 [7.38–7.40] |
Paco2 before start of study (mm Hg, median [IQR]) |
|
5.2 [4.8–5.2] |
5.2 [4.8–5.2] |
ETCO2 before start of study (mm Hg, median [IQR]) |
|
4.8 [4.5–4.9] |
4.8 [4.5–4.9] |
Haemoglobin before start of study (g dl−1, median [IQR]) |
|
11.4 [9.8–12.1] |
11.4 [10.0–11.9] |
Haematocrit before start of study (%, median [IQR]) |
|
34 [29–35] |
34 [30–35] |
Baseline MAP before induction of anaesthesia (mm Hg, median [IQR]) |
|
98 [96–101] |
98 [93–105] |